To Stay Up to Date on Awards and RFAs, Sign Up for Notifications via Email Below
"*" indicates required fields
Current & Closed RFAs
Closed
Request for Letters of Intent: 2026 PCF TACTICAL Awards
IMPORTANT: Applying for a PCF TACTICAL Award (Therapy ACceleration To Intercept CAncer Lethality) involves a 2-stage process. PCF requires a Letter of Intent (LOI), followed by full application submission upon our invitation.
The Prostate Cancer Foundation (PCF) is pleased to announce a Request for LOIs for PCF TACTICAL Awards from qualified teams of investigators from academic and community institutions that will directly contribute to improved outcomes for patients with prostate cancer with lethal potential. These awards will be funded depending on the level of innovation and transformative potential in applications received. PCF seeks high-risk, currently unfunded projects from academic and community research institutions around the world. TACTICAL Awards provide $5 – $10 Million U.S.D. per award over 3–5 years.
Monday, March 16, 2026, 11:59 p.m. Eastern Daylight Time (EDT)
Deadline for emailing LOI to [email protected]
Please direct questions to [email protected]
Closed
Request for Applications: 2026 PCF Young Investigator Awards
The Prostate Cancer Foundation (PCF) is pleased to announce a new round of funding for PCF Young Investigators.
PCF Young Investigator Awards will be three (3) years in duration and will provide $75,000 per year. The award funds may be used innovatively and flexibly to advance the career and research efforts of the awardee. This for example, includes funding ‘protected time’ or direct costs for laboratory science. This award does not support indirect costs such as institutional overhead. Every PCF Young Investigator is required to have at least 1 mentor. PCF Award recipients are required to submit progress reports on time to receive additional payments. Young Investigator awardees are required to attend the Annual PCF Scientific Retreat and Young Investigator Forum, typically held in October, throughout the duration of their award; PCF will separately cover most costs for this travel requirement.
These awards will include one ASTRO-PCF Young Investigator Award selected from qualified applicants (a radiation oncologist, radiation or cancer biologist, or radiation physicist).
Monday, January 12, 2026
The online application submission portal opens.
Monday, February 23, 2026, 3:00 pm, Eastern Daylight Time (EDT)
The submission deadline for applications.
Please direct questions to [email protected].
Closed
Request for Proposals: 2026 PCF Challenge Awards
The Prostate Cancer Foundation (PCF) is pleased to announce a Request for Applications for PCF Challenge Awards for Team Science investigations of prostate cancer with lethal potential. These awards will be funded depending on the level of innovation in applications received. PCF seeks high-risk, currently unfunded projects from academic and community research institutions around the world.
Monday, January 12, 2026
The online application submission portal opens.
Monday, March 16, 2026, 3:00 p.m. Eastern Daylight Time (EDT)
The submission deadline for applications.
Please direct questions to [email protected].
Closed
Request for Applications: 2026 SNMMI – PCF Young Investigator Award
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and Prostate Cancer Foundation (PCF) announce a Request For Applications (RFA) for a 2026 SNMMI Mars Shot Research Fund (MSRF) – PCF Young Investigator Award.Applicants must be members of SNMMI.
For the purposes of this application, the science submitted should focus on research addressing unmet medical needs in the diagnosis and treatment of potentially lethal prostate cancer.
The SNMMI-PCF Young Investigator Award will be three (3) years in duration and will provide $75,000 per year. The award funds may be used innovatively and flexibly to advance the career and research efforts of the awardee. This, for example, includes funding “protected time” or direct costs for laboratory science. This award does not support indirect costs such as institutional overhead. Every PCF Young Investigator is required to be under the direct supervision of 1-3 mentors. Young Investigator awardees are required to attend the Annual PCF Scientific Retreat and Young Investigator Forum, typically held in October, throughout the duration of their award (travel funding will be covered).
We seek applications from early-career nuclear medicine physicians, nuclear radiologists, basic scientists, medical oncologists, pathologists, urologists, radiologists, radiation oncologists, public health experts, bioinformaticians, bioengineers, or professionals from any other field that could contribute to the end of potentially lethal prostate cancer. Applicants may be working in basic, translational, computational or clinical research and need not be trained specifically in prostate cancer research to be highly competitive. However, successful applicants should be working in an academic research environment capable of supporting transformational prostate cancer research. Access to and real-time interaction with a clinical environment and translational prostate cancer physician-scientists are highly desired. Applicants traditionally under-represented in science and medicine are highly encouraged. Awardees must be members of the SNMMI at the time of the award and during the award period.
To view the RFA and apply (SNMMI members only): https://snmmi.secure-platform.com/site/solicitations/113/home
The application submission deadline is Monday, December 1, 2025.
Please direct questions to Teresa Ellmer at [email protected].
Closed
Request for Letters of Intent: 2025 PCF TACTICAL Awards
IMPORTANT: Applying for a PCF TACTICAL Award (Therapy ACceleration To Intercept CAncer Lethality) involves a 3-stage process. PCF requires a Letter of Intent (LOI), followed by full application submission upon our invitation. Following peer review, top applicants will undergo a Zoom-based interview. See page 2 for details.
The Prostate Cancer Foundation (PCF) is pleased to announce a Request for LOIs for PCF TACTICAL Awards from qualified teams of academic scientists that will specifically address the development of 21st Century therapies for lethal forms of prostate cancer. These awards will be funded depending on the level of innovation in applications received. PCF seeks high-risk, currently unfunded projects from academic institutions around the world. TACTICAL Awards provide $5 – $10 Million U.S.D. per award over 3–5 years.
Monday, May 19, 2025, 11:59 p.m. Eastern Daylight Time (EDT)
Deadline for emailing LOI to [email protected]
Please direct questions to [email protected].
Closed
Request for Proposals: 2025 PCF Challenge Awards
The Prostate Cancer Foundation (PCF) is pleased to announce a Request for Team Science Applications for PCF Challenge Awards for investigations of metastatic, lethal prostate cancer. These awards will be funded depending on the level of innovation in applications received. PCF seeks high-risk, currently unfunded projects from academic institutions around the world.
Monday, May 5, 2025, 3:00 p.m. Eastern Daylight Time (EDT)
Application submission deadline
Please direct questions to [email protected].
Closed
Request for Applications: 2025 PCF Young Investigator Awards
The Prostate Cancer Foundation (PCF) is pleased to announce a new round of funding for PCF Young Investigators. We especially encourage young investigators working on prostate cancer health disparities to apply.
PCF Young Investigator Awards will be three (3) years in duration and will provide $75,000 per year. The award funds may be used innovatively and flexibly to advance the career and research efforts of the awardee. This for example, includes funding “protected time” or direct costs for laboratory science. This award does not support indirect costs such as institutional overhead. Every PCF Young Investigator is required to be under the direct supervision of 1-3 mentors. Young Investigator awardees are required to attend the Annual PCF Scientific Retreat and Young Investigator Forum, typically held in October, throughout the duration of their award.
Research proposals addressing disparities in care experienced by patients with prostate cancer may focus on implementation research in various populations (e.g., urban vs rural, racial, geographic or financial) or in drivers of care and outcome disparities that could potentially be addressed through changes in policy, advocacy or education. Applicants are encouraged to solicit and integrate advice from patients, patient support groups or advocates. Letters of support demonstrating such relationships are recommended.
Monday, January 6, 2025
The online application submission portal opens.
Monday, March 10, 2025 3:00 Eastern Daylight Time (EDT)
The submission deadline for applications.
Please direct questions to [email protected].
Closed
Request for Letters of Intent: 2024 PCF Challenge Awards
IMPORTANT: Applying for a Challenge Award involves a 2-stage process. PCF requires a Letter of Intent (LOI), followed by full application submission upon our approval. See the RFA for online submission details.
The Prostate Cancer Foundation (PCF) is pleased to announce a Request for Team Science Applications for PCF Challenge Awards for investigations of metastatic, lethal prostate cancer. These awards will be funded depending on the level of innovation in applications received. PCF seeks high-risk, currently unfunded projects from academic institutions around the world.
We especially encourage applications on prostate cancer disparity research that will help to define the origins of differential outcome for prostate cancer patients in men of under-represented populations, including those focusing on biology or health care access policy. We also seek applications conducting research in VA hospitals where research directly affects veterans with advanced prostate cancer.
Monday, February 26 2024
The Letter of Intent (LOI) Portal opens
Monday, April 8 2024, 3:00 pm, Eastern Daylight Time (EDT)
The LOI submission deadline
Please direct questions to [email protected].
Closed
Request for Proposals (RFP): Visiting Professorship Program
The Prostate Cancer Foundation (PCF) and Pfizer Inc. Improving Advanced Prostate Cancer Management in Latin America
This RFP is to provide financial support to organizations to host and coordinate a two-day medical education program at the organization, to be led by two international Visiting Professors with expertise matched to the organization’s unmet educational needs surrounding the management of advanced prostate cancer, so that healthcare practitioners, researchers and patients can benefit from the knowledge and on-site presence of distinguished medical experts who might otherwise be inaccessible. Our intent to support this first-time competitive VP Program for Latin America, reflects our commitment to improve outcomes for patients with advanced prostate cancer and to advance research, innovation, clinical expertise, and education for healthcare professionals in Latin America.
Geographic Scope: Argentina, Brazil, Chile, Colombia, and Mexico
Clinical Area: Oncology — Genitourinary — Prostate Cancer
Target Audience: Medical oncologists should serve as Principal Investigator (PI) and Program Chair, but all other medical disciplines can be included in the Program plan, such as: radio-oncologists, allied prostate cancer healthcare providers, and urology, pathology and nuclear medicine MDs.
April 4, 2024, 23:59 Eastern Daylight Time (EDT)
Grant Application Due Date
Please direct questions to Miguel Briceno ([email protected]) with the subject line: 2024 ONC LATAM Improving Advanced Prostate Cancer Management in Latin America IME..
Closed
Request for Applications: 2024 PCF Young Investigator Awards
The Prostate Cancer Foundation (PCF) is pleased to announce a new round of funding for PCF Young Investigators. We especially encourage young investigators working on prostate cancer health disparities to apply.
PCF Young Investigator Awards will be three (3) years in duration and will provide $75,000 per year. The award funds may be used innovatively and flexibly to advance the career and research efforts of the awardee. This for example, includes funding “protected time” or direct costs for laboratory science. This award does not support indirect costs such as institutional overhead. Every PCF Young Investigator is required to be under the direct supervision of 1-3 mentors. Young Investigator awardees are required to attend the Annual PCF Scientific Retreat and Young Investigator Forum, typically held in October, throughout the duration of their award.
Research proposals addressing disparities in care experienced by patients with prostate cancer may focus on implementation research in various populations (e.g. urban vs rural, racial, geographic or financial) or in drivers of care and outcome disparities that could potentially be addressed through changes in policy, advocacy or education. Applicants are encouraged to solicit and integrate advice from patients, patient support groups or advocates. Letters of support demonstrating such relationships are recommended.
Monday, January 29, 2024
Online submission Portal opens
Monday, April 15, 2024, 3:00 pm, Eastern Daylight Time (EDT)
Submission deadline
Please direct questions to [email protected].
Closed
Request for Applications (U.S. Only): 2023 Bayer-PCF Health Equity Research Awards
IMPORTANT: Applying for a Bayer-PCF Health Equity Research Award involves a 2-stage process. A Letter of Intent (LOI) is first required, followed by full application submission upon our invitation. See RFA for details.
The Prostate Cancer Foundation (PCF) and Bayer are pleased to announce a Request for Team Science Applications for Bayer-PCF Health Equity Research Awards for novel health equity implementation research projects with the goal of reducing racial and ethnic disparities in the diagnosis and treatment of advanced prostate cancer. These awards will be funded depending on the level of innovation in applications received. PCF and Bayer seek high-risk, currently unfunded projects from academic institutions in the United States (U.S. only).
Friday, May 5, 2023, 3:00 pm, Eastern Daylight Time (EDT)
Deadline for emailing LOI to [email protected].
Please direct questions to [email protected].
Closed
Request for Applications (U.S. only): 2023 Bayer-PCF Darolutamide Challenge Awards
The Prostate Cancer Foundation (PCF) and Bayer are pleased to announce a Request for Team Science Applications for Bayer-PCF Challenge Awards for novel investigator-initiated clinical investigations with correlative research for darolutamide in prostate cancer. These awards will be funded depending on the level of innovation in applications received. PCF and Bayer seek high-risk, currently unfunded projects from academic institutions in the United States (U.S. only).
Friday, March 31, 2023
Online submission Portal opens.
Monday, June 5, 2023, 3:00 pm, Eastern Daylight Time (EDT)
Submissions deadline
Please direct questions to [email protected].
Closed
Request for Letters of Intent: 2023 PCF Young Investigator Awards
IMPORTANT: This year, applying for a PCF Young Investigator Award involves a 2-stage process. PCF requires a Letter of Intent (LOI), followed by full application submission upon our invitation. See RFA for details.
The Prostate Cancer Foundation (PCF) is pleased to announce a request for applications for Young Investigator Awards. We especially encourage young investigators working on prostate cancer health disparities to apply.
PCF Young Investigator Awards will be three (3) years in duration and will provide $75,000 per year. The award funds may be used innovatively and flexibly to advance the career and research efforts of the awardee. This for example, includes funding “protected time” or direct costs for laboratory science. This award does not support indirect costs such as institutional overhead. Every PCF Young Investigator is required to be under the direct supervision of 1-3 mentors. Young Investigator awardees are required to attend the Annual PCF Scientific Retreat and Young Investigator Forum, typically held in October, throughout the duration of their award.
Research proposals addressing disparities in care experienced by patients with prostate cancer may focus on implementation research in various populations (e.g. urban vs rural, racial, geographic or financial) or in drivers of care and outcome disparities that could potentially be addressed through changes in policy, advocacy or education. Applicants are encouraged to solicit and integrate advice from patients, patient support groups or advocates. Letters of support demonstrating such relationships are recommended.
Friday, February 10, 2023, 3:00 pm, Eastern Standard Time (EST)
Deadline for emailing LOI to [email protected].
Please direct questions to [email protected].
Closed
Request for Letters of Intent: 2023 PCF Challenge Awards
IMPORTANT: This year, applying for a PCF Challenge Award involves a 2-stage process. PCF requires a Letter of Intent (LOI), followed by full application submission upon our invitation. See RFA for details.
The Prostate Cancer Foundation (PCF) is pleased to announce a Request for Team Science Applications for PCF Challenge Awards for investigations of metastatic, lethal prostate cancer. These awards will be funded depending on the level of innovation in applications received. PCF seeks high-risk, currently unfunded projects from academic institutions around the world. We especially encourage applications on prostate cancer disparity research that will help to define the origins of differential outcome for prostate cancer patients in men of under-represented populations, including those focusing on biology or health care access policy. We also seek applications conducting research in VA hospitals where research directly affects veterans with advanced prostate cancer.
Friday, March 10, 2023, 3:00 pm, Eastern Daylight Time (EDT)
Deadline for emailing LOI to [email protected].
Please direct questions to [email protected].
Closed
Request for Letters of Intent: 2022 PCF Challenge Awards
IMPORTANT: This year, applying for a Challenge Award involves a 2-stage process. PCF requires a Letter of Intent (LOI), followed by full application submission upon our invitation. See RFA for details.
The Prostate Cancer Foundation (PCF) is pleased to announce a Request for Team Science Applications for PCF Challenge Awards for investigations of metastatic, lethal prostate cancer. These awards will be funded depending on the level of innovation in applications received. High risk, currently unfunded projects are most desired.
Detailed instructions on completing the LOI form can be found on page 2 of the RFA.
Monday, April 11, 2022
Deadline for submitting form to [email protected].
Please direct questions to [email protected].
Closed
Request for Letters of Intent: 2022 PCF TACTICAL Awards (Therapy ACceleration To Intercept CAncer Lethality)
IMPORTANT: Applying for a PCF TACTICAL Award (Therapy ACceleration To Intercept CAncer Lethality) involves a 3-stage process. PCF requires a Letter of Intent (LOI), followed by full application submission upon our invitation. Following peer review, top applicants will undergo a Zoom-based interview. See RFA for details.
The Prostate Cancer Foundation (PCF) is pleased to announce a Request for LOIs for PCF TACTICAL Awards from qualified teams of academic scientists that will specifically address the development of 21st Century therapies for lethal forms of prostate cancer. These awards will be funded depending on the level of innovation in applications received. PCF seeks high-risk, currently unfunded projects from academic institutions around the world. PCF will fund 2-3 of these three-year awards for $5 – $10 Million U.S.D. per award.
For more information, please view the brief video Chuck Ryan and Howard Soule produced to describe this funding mechanism: Watch Video
Monday, June 20, 2022
Deadline for submitting LOI to [email protected].
Please direct questions to [email protected].
Closed
Request for Applications: 2022 PCF Young Investigator Awards
The Prostate Cancer Foundation (PCF) is pleased to announce a request for applications for Young Investigator Awards. We especially encourage young investigators working on prostate cancer health disparities to apply.
PCF Young Investigator Awards will be three (3) years in duration and will provide $75,000 per year. The award funds may be used innovatively and flexibly to advance the career and research efforts of the awardee. This for example, includes funding “protected time” or direct costs for laboratory science. This award does not support indirect costs such as institutional overhead. Every PCF Young Investigator is required to be under the direct supervision of 1-3 mentors. Young Investigator awardees are required to attend the Annual PCF Scientific Retreat and Young Investigator Day, typically held in October, throughout the duration of their award.
PCF seeks applications from the global biomedical research community. Applicants traditionally under-represented in science and medicine are highly encouraged. We seek applications from early-career basic scientists, medical oncologists, pathologists, urologists, radiologists, radiation oncologists, public health experts, bioinformaticians, bioengineers, or professionals from any other field that could contribute to the end of prostate cancer. Applicants may be working in basic, translational, computational or clinical research and need not be trained specifically in prostate cancer research to be highly competitive. However, successful applicants should be working in an academic research environment capable of supporting transformational prostate cancer research. Access to and real-time interaction with a clinical environment and translational prostate cancer physician-scientists is highly desired.
Research proposals addressing disparities in care experienced by patients with prostate cancer may focus on implementation research in various populations (e.g. urban vs rural, racial, geographic or financial) or in biological drivers of care and outcome disparities that could potentially be addressed through changes in policy, advocacy or education. Applicants are encouraged to solicit and integrate advice from patients, patient support groups or advocates. Letters of support demonstrating such relationships are recommended.
Veterans Administration (VA) Hospital Applicants and Projects
In order to improve the health and wellness of our treasured US military veterans, applicants with Veterans Administration (VA) appointments are highly encouraged to apply. Projects that involve a VA Medical Center in their research proposal planning will be appreciated. This may include but is not limited to (1) creation of defined cohorts of prostate cancer patients annotated with the VA electronic medical record for the purpose of population science research; (2) blood, tissue or other body fluid specimens collection from VA prostate cancer patients for translational or clinical trial correlate research; (3) development of new biotechnologies for the diagnosis or treatment of prostate cancer patients within the VA healthcare system; (4) activation of novel IRB- and FDA-approved phase 1 and 2 clinical investigations; (5) unique genomic investigations of tumor or germline specimens from VA prostate cancer patients with the goal of understanding the unique mutations that might have occurred due to battlefield exposure to specific toxic materials; (6) precision medicine clinical trials matching pathogenic germline or tumor alterations to experimental or FDA-approved medications.
February 4, 2022
Online submissions Portal opens
Monday, April 25, 2022 3:00 pm, Eastern Daylight Time (EDT)
Deadline for submissions
Closed
Request for Applications: PCF-Pfizer-Myovant Relugolix Challenge Awards
Pfizer Inc., the Prostate Cancer Foundation (PCF) and Myovant Sciences GmbH are proud to announce the PCF-Pfizer-Myovant Relugolix Challenge Awards, a competitive, peer-reviewed Independent Research grants program for investigators based in the United States.
The intent of this Request for Proposals (RFP) is to invite academic investigators to submit innovative proposals for clinical investigations with correlative research for relugolix in prostate cancer.
Monetary Range of Grant Awards:
- The target budget for each individual project grant is up to $500,000. However, individual projects requesting up to $750,000 will be considered.
- Applications will be reviewed by an expert review panel (ERP) led by PCF.
- The amount of the grant Pfizer will be prepared to fund for any project will depend upon the expert review panel’s evaluation of the proposal and costs involved, and will be stated clearly in the grant agreement.
How to Apply:
- Please go to www.cybergrants.com/pfizer/Research and sign in. First-time users should click “Create your password”.
- In the application:
- For the question “Are you replying to a Request for Proposal as part of the Competitive Grant Program?” select ‘Yes’
- Select the following Competitive Grant Program Name: 2021 PCF-Pfizer-Myovant Relugolix Challenge Awards
- Select the following Primary Area of Interest: Oncology — Genitourinary — Prostate Cancer
- Requirements for submission:
- Complete all required sections of the online application and upload your project proposal (see Appendix) in the Proposal/Protocol field.
- If you encounter any technical difficulties with the website, please click the “Technical Questions” link at the bottom of the page.
June 7, 2021
RFP release date
August 16, 2021, 23:59 Eastern Time (New York, GMT –5)
Application Due Date
October 11, 2021
Anticipated Grant Award Notification Date
December 2021 – November 2023
Anticipated project start and end dates
Please direct questions to Dewayne Brumlow at ([email protected]) or Jennifer Smith at ([email protected]) with the subject line “2021 PCF-Pfizer-Myovant Relugolix Challenge Awards”
Closed
Request for LOI Applications – PCF-Pfizer Health Equity Challenge Awards
Pfizer Inc. and the Prostate Cancer Foundation (PCF) are proud to announce the PCF-Pfizer Health Equity Challenge Awards, a competitive, peer-reviewed Independent Research grants program for investigators across the globe.
The intent of this program is to support general research projects that will improve the understanding of or reduce disparities in the diagnosis, management, and outcomes of prostate cancer patients in minority and underserved communities.
Monetary Range of Grant Awards
- Expected individual grant amounts are in the range of $100K to $150K.
- Approximately $1.5 million USD are allocated to this RFP.
- Applications will be reviewed by an expert review panel (ERP) led by PCF.
- The amount of the grant Pfizer will be prepared to fund for any project will depend upon the expert review panel’s evaluation of the proposal and costs involved, and will be stated clearly in the grant agreement.
How to Apply:
- Please go to www.cybergrants.com/pfizer/loi and sign in. First-time users should click “Create your password.”
- Select the following Competitive Grant Program Name: 2021 Oncology G: PCF-Pfizer Health Equity Challenge Awards
- Complete all required sections of the online application. See Appendix A for additional details.
- If you encounter any technical difficulties with the website, please click the “Technical Questions” link at the bottom of the page.
Please click Here to view Frequently Asked Questions regarding the Competitive Grant Program.
Please direct questions to Dewayne Brumlow ([email protected]), with the subject line: “2021 PCF-Pfizer Health Equity Challenge Awards”
February 10, 2021
RFP release date
April 9, 2021, 11:59 pm, Eastern Time (New York, GMT –5)
Letter of Intent (LOI) due date
June 30, 2021
Anticipated LOI Notification Date
August 30, 2021, 11:59 pm, Eastern Time (New York, GMT –5)
Full Proposal Deadline (Only accepted LOIs will be invited to submit full proposals)
November 19, 2021
Anticipated Full Proposal Notification Date
